BACKGROUND: Skewed X chromosome inactivation may be more common in women with epithelial ovarian cancer and early-onset breast cancer. We tested this hypothesis in a group of 235 breast cancer patients and 253 controls (mean age 45.8 years) from a larger population based case control study. METHODS: We measured X chromosome inactivation with the AR gene assay in lymphocyte DNA digested with the methylation specific enzyme HpaII. We judged skewness using an adjusted measure (relative to the undigested sample) with a cut point of 75%, and an unadjusted measure where skewed was defined as > 90% of the signal from one allele in the HpaII digested sample. RESULTS: There were no significant differences in any of the skewing measures between cases and controls. Using the adjusted skewing measure among pre-menopausal subjects under the age of 50, 14% of cases versus 11% of controls were skewed, OR = 1.2, 95% CI 0.6 to 2.3; using the unadjusted measure, OR = 0.9, 95% CI 0.4 to 2.0. CONCLUSIONS: While we cannot rule out a subtle difference of approximately twofold or less, we have failed to find a significant difference in the prevalence of skewed X chromosome inactivation in younger women with breast cancer compared to controls.
BACKGROUND: Skewed X chromosome inactivation may be more common in women with epithelial ovarian cancer and early-onset breast cancer. We tested this hypothesis in a group of 235 breast cancerpatients and 253 controls (mean age 45.8 years) from a larger population based case control study. METHODS: We measured X chromosome inactivation with the AR gene assay in lymphocyte DNA digested with the methylation specific enzyme HpaII. We judged skewness using an adjusted measure (relative to the undigested sample) with a cut point of 75%, and an unadjusted measure where skewed was defined as > 90% of the signal from one allele in the HpaII digested sample. RESULTS: There were no significant differences in any of the skewing measures between cases and controls. Using the adjusted skewing measure among pre-menopausal subjects under the age of 50, 14% of cases versus 11% of controls were skewed, OR = 1.2, 95% CI 0.6 to 2.3; using the unadjusted measure, OR = 0.9, 95% CI 0.4 to 2.0. CONCLUSIONS: While we cannot rule out a subtle difference of approximately twofold or less, we have failed to find a significant difference in the prevalence of skewed X chromosome inactivation in younger women with breast cancer compared to controls.
Authors: Shridar Ganesan; Daniel P Silver; Roger A Greenberg; Dror Avni; Ronny Drapkin; Alexander Miron; Samuel C Mok; Voahangy Randrianarison; Steven Brodie; Jennifer Salstrom; Theodore P Rasmussen; Ann Klimke; Christine Marrese; York Marahrens; Chu Xia Deng; Jean Feunteun; David M Livingston Journal: Cell Date: 2002-11-01 Impact factor: 41.582
Authors: C L Beever; M D Stephenson; M S Peñaherrera; R H Jiang; D K Kalousek; M Hayden; L Field; C J Brown; W P Robinson Journal: Am J Hum Genet Date: 2002-12-20 Impact factor: 11.025
Authors: E Giovannucci; M J Stampfer; K Krithivas; M Brown; D Dahl; A Brufsky; J Talcott; C H Hennekens; P W Kantoff Journal: Proc Natl Acad Sci U S A Date: 1997-04-01 Impact factor: 11.205
Authors: Jennifer H Fergenbaum; Montserrat Garcia-Closas; Stephen M Hewitt; Jolanta Lissowska; Lori C Sakoda; Mark E Sherman Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-04 Impact factor: 4.254
Authors: Jonas Mengel-From; Mikael Thinggaard; Lene Christiansen; James W Vaupel; Karen Helene Orstavik; Kaare Christensen Journal: Eur J Hum Genet Date: 2011-12-07 Impact factor: 4.246
Authors: Stacey J Winham; Nicholas B Larson; Sebastian M Armasu; Zachary C Fogarty; Melissa C Larson; Brian M McCauley; Chen Wang; Kate Lawrenson; Simon Gayther; Julie M Cunningham; Brooke L Fridley; Ellen L Goode Journal: Hum Mol Genet Date: 2019-04-15 Impact factor: 6.150